Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Basu

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Cell Reports|March 5, 2026
Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrierSaurabh K Garg, Colin Snyder, Ganesan Ramamoorthi, et al.
Breast Cancer Research : BCR|October 4, 2023
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancerTessa G Steenbruggen, Denise M Wolf, Michael J Campbell, et al.
Cancer Immunology Research|November 17, 2021
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4<sup>+</sup> Th1 Responses and Potential Use as a Cancer VaccineAmrita Basu, Gabriella K Albert, Sabrina Awshah, et al.
JCO Clinical Cancer Informatics|February 21, 2020
Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient OutcomesJill S Barnholtz-Sloan, Dana E Rollison, Amrita Basu, et al.
The Journal of Allergy and Clinical Immunology|February 4, 2026
A clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseasesMichael T Lam, Amrita Basu, Kailey E Brodeur, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
Nature|June 11, 2025
Glycosaminoglycan-driven lipoprotein uptake protects tumours from ferroptosisDylan Calhoon, Lingjie Sang, Fubo Ji, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Cell Reports|March 5, 2026
Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrierSaurabh K Garg, Colin Snyder, Ganesan Ramamoorthi, et al.
Breast Cancer Research : BCR|October 4, 2023
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancerTessa G Steenbruggen, Denise M Wolf, Michael J Campbell, et al.
Cancer Immunology Research|November 17, 2021
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4<sup>+</sup> Th1 Responses and Potential Use as a Cancer VaccineAmrita Basu, Gabriella K Albert, Sabrina Awshah, et al.
JCO Clinical Cancer Informatics|February 21, 2020
Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient OutcomesJill S Barnholtz-Sloan, Dana E Rollison, Amrita Basu, et al.
The Journal of Allergy and Clinical Immunology|February 4, 2026
A clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseasesMichael T Lam, Amrita Basu, Kailey E Brodeur, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
Nature|June 11, 2025
Glycosaminoglycan-driven lipoprotein uptake protects tumours from ferroptosisDylan Calhoon, Lingjie Sang, Fubo Ji, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 23, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT studyMark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Pageof 8